HSP .90 eps qtr shows that its newly launched Chemo drug will have a major effect
on its eps in future quarters.
Hospira said sales of specialty drugs -- or drugs that require special handling -- climbed 24 percent to $575.7 million. That was partly due to sales of a generic version of the chemotherapy drug oxaliplatin, which was launched during the quarter.
Oxaliplatin is a generic version of Sanofi-Aventis' drug Eloxatin.